These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26022569)

  • 1. Vaccines: from valuation to resource allocation.
    Bloom DE; Madhavan G
    Vaccine; 2015 Jun; 33 Suppl 2():B52-4. PubMed ID: 26022569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valuing vaccines: deficiencies and remedies.
    Bloom DE
    Vaccine; 2015 Jun; 33 Suppl 2():B29-33. PubMed ID: 26022563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What have we learned on costs and financing of routine immunization from the comprehensive multi-year plans in GAVI eligible countries?
    Brenzel L
    Vaccine; 2015 May; 33 Suppl 1():A93-8. PubMed ID: 25919183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moving beyond traditional valuation of vaccination: Needs and opportunities.
    Bloom DE; Brenzel L; Cadarette D; Sullivan J
    Vaccine; 2017 Jan; 35 Suppl 1():A29-A35. PubMed ID: 28017436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs of vaccine programs across 94 low- and middle-income countries.
    Portnoy A; Ozawa S; Grewal S; Norman BA; Rajgopal J; Gorham KM; Haidari LA; Brown ST; Lee BY
    Vaccine; 2015 May; 33 Suppl 1():A99-108. PubMed ID: 25919184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Building the Human Vaccines Project: strategic management recommendations and summary report of the 15-16 July 2014 business workshop.
    Schenkelberg T; Kieny MP; Bianco AE; Koff WC
    Expert Rev Vaccines; 2015 May; 14(5):629-36. PubMed ID: 25673514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine development costs: a review.
    Waye A; Jacobs P; Schryvers AB
    Expert Rev Vaccines; 2013 Dec; 12(12):1495-501. PubMed ID: 24160863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Examining the cost of delivering routine immunization in Honduras.
    Janusz CB; Castañeda-Orjuela C; Molina Aguilera IB; Felix Garcia AG; Mendoza L; Díaz IY; Resch SC
    Vaccine; 2015 May; 33 Suppl 1():A53-9. PubMed ID: 25919175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ProVac Global Initiative: a vision shaped by ten years of supporting evidence-based policy decisions.
    Jauregui B; Janusz CB; Clark AD; Sinha A; Garcia AG; Resch S; Toscano CM; Sanderson C; Andrus JK
    Vaccine; 2015 May; 33 Suppl 1():A21-7. PubMed ID: 25919164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strengthening vaccination policies in Latin America: an evidence-based approach.
    Tapia-Conyer R; Betancourt-Cravioto M; Saucedo-Martínez R; Motta-Murguía L; Gallardo-Rincón H
    Vaccine; 2013 Aug; 31(37):3826-33. PubMed ID: 23357196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health economic research on vaccinations and immunisation practices--an introductory primer.
    Szucs TD
    Vaccine; 2005 Mar; 23(17-18):2095-103. PubMed ID: 15755578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Vaccines: building on scientific excellence and dispelling false myths].
    Signorelli C
    Epidemiol Prev; 2015; 39(3):198-201. PubMed ID: 26522283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Scientific challenges and opportunities in developing novel vaccines for the emerging and developing markets: New Technologies in Emerging Markets, October 16th-18th 2012, World Vaccine Congress, Lyon.
    Kochhar S
    Hum Vaccin Immunother; 2013 Apr; 9(4):928-31. PubMed ID: 23322007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs and financing of routine immunization: Approach and selected findings of a multi-country study (EPIC).
    Brenzel L; Young D; Walker DG
    Vaccine; 2015 May; 33 Suppl 1():A13-20. PubMed ID: 25919153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of health economic analyses in vaccine decision making.
    Black S
    Vaccine; 2013 Dec; 31(51):6046-9. PubMed ID: 23968768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspectives on the development and use of economic evidence for immunization decision-making in a developing country.
    Molina-Aguilera IB
    Vaccine; 2015 May; 33 Suppl 1():A6-7. PubMed ID: 25919176
    [No Abstract]   [Full Text] [Related]  

  • 17. Tracking financial flows for immunization in Honduras.
    Valdés W; Janusz CB; Molina Aguilera IB; Mendoza L; Díaz IY; Resch S
    Vaccine; 2015 May; 33 Suppl 1():A85-92. PubMed ID: 25919182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costs of routine immunization and the introduction of new and underutilized vaccines in Ghana.
    Le Gargasson JB; Nyonator FK; Adibo M; Gessner BD; Colombini A
    Vaccine; 2015 May; 33 Suppl 1():A40-6. PubMed ID: 25919173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perspectives on expanding the evidence base to inform vaccine introduction: Program costing and cost-effectiveness analyses.
    Andrus JK; Walker DG
    Vaccine; 2015 May; 33 Suppl 1():A2-3. PubMed ID: 25919161
    [No Abstract]   [Full Text] [Related]  

  • 20. Foreword.
    Etienne CF
    Vaccine; 2015 May; 33 Suppl 1():A1. PubMed ID: 25919148
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.